BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2809684)

  • 1. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
    Helman LJ; Cohen PS; Averbuch SD; Cooper MJ; Keiser HR; Israel MA
    J Clin Oncol; 1989 Nov; 7(11):1720-5. PubMed ID: 2809684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.
    Thouënnon E; Pierre A; Tanguy Y; Guillemot J; Manecka DL; Guérin M; Ouafik L; Muresan M; Klein M; Bertherat J; Lefebvre H; Plouin PF; Yon L; Anouar Y
    Endocr Relat Cancer; 2010 Sep; 17(3):637-51. PubMed ID: 20483910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of neuropeptide Y mRNA expression in cultured human pheochromocytoma cells.
    Liu J; Kahri AI; Heikkilä P; Voutilainen R
    Eur J Endocrinol; 1999 Oct; 141(4):431-5. PubMed ID: 10526260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
    Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
    Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
    Salmenkivi K; Haglund C; Ristimäki A; Arola J; Heikkilä P
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5615-9. PubMed ID: 11701743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of expression of neuropeptide Y mRNA in human phaeochromocytomas.
    Higuchi H; Iwasa A; Yokokawa K
    Clin Exp Pharmacol Physiol; 1994 May; 21(5):359-65. PubMed ID: 7955545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential heparanase-1 expression in malignant and benign pheochromocytomas.
    Quiros RM; Kim AW; Maxhimer J; Gattuso P; Xu X; Prinz RA
    J Surg Res; 2002 Nov; 108(1):44-50. PubMed ID: 12443714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
    Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
    Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic management of benign and malignant pheochromocytoma.
    Scholz T; Schulz C; Klose S; Lehnert H
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry.
    Hofland J; van Nederveen FH; Timmerman MA; Korpershoek E; de Herder WW; Lenders JW; Verhofstad AA; de Krijger RR; de Jong FH
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):335-40. PubMed ID: 17302865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
    Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
    Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas.
    Grouzmann E; Gicquel C; Plouin PF; Schlumberger M; Comoy E; Bohuon C
    Cancer; 1990 Oct; 66(8):1833-5. PubMed ID: 2208039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
    Thouënnon E; Elkahloun AG; Guillemot J; Gimenez-Roqueplo AP; Bertherat J; Pierre A; Ghzili H; Grumolato L; Muresan M; Klein M; Lefebvre H; Ouafik L; Vaudry H; Plouin PF; Yon L; Anouar Y
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4865-72. PubMed ID: 17878247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
    Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
    J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
    Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct expression of galectin-3 in pheochromocytomas.
    Gimm O; Krause U; Brauckhoff M; Hoang-Vu C; Dralle H
    Ann N Y Acad Sci; 2006 Aug; 1073():571-7. PubMed ID: 17102125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stathmin as a marker for malignancy in pheochromocytomas.
    Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
    Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.
    Boltze C; Mundschenk J; Unger N; Schneider-Stock R; Peters B; Mawrin C; Hoang-Vu C; Roessner A; Lehnert H
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4280-6. PubMed ID: 12970299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytomas, PASS, and immunohistochemistry.
    Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
    Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.